Signalpoint

← Full daily brief

Business brief

Pharma Wins and Financial Issuance Drive Corporate Session

Teva reports positive Phase 2a celiac trial results, Bank Leumi prices a €750 million bond in Europe, and Check Point secures shareholder approval at its annual meeting.

Signalpoint TeamBrief

Business

Check Point secured complete shareholder backing for its board and executive pay — maintaining governance stability as cybersecurity market competition intensifies.

BackgroundCheck Point is a Tel Aviv-headquartered cybersecurity vendor dual-listed on NASDAQ and traded globally. Annual governance votes govern board appointments and executive compensation frameworks required under statutory Israeli corporate regulations.

Points
  1. Shareholders re-elected seven board directors and ratified independent accounting appointments, securing administrative stability for the upcoming fiscal year.
  2. Executive compensation frameworks passed following alignment with institutional proxy advisory recommendations, preventing potential pay disputes with major shareholders.
  3. Over 81.2 million ordinary shares were voted during the annual meeting, representing high institutional turnout and broad backing for current leadership.
SourcesSEC.gov: Check Point Software Technologies Ltd. Form 6-K (opens in new tab)StockTitan: Check Point shareholders back all AGM proposals (opens in new tab)

Business

Bank Leumi's €750M bond sale shows European institutional demand for Israeli bank debt remains strong as digital migration slashes operational costs.

BackgroundIsraeli banking institutions regularly utilize European covered bond markets to secure long-term, fixed-rate wholesale debt funding. Bank Leumi has driven cost-cutting measures by transitioning private banking clients to automated digital platforms.

Points
  1. The fixed-rate bond issue was oversubscribed by European asset managers, confirming solid international demand for top-tier Israeli financial debt.
  2. Capital raised will back Leumi's residential mortgage portfolio expansion across domestic growth centers, expanding its core retail lending business.
  3. Digital adoption across 90% of private accounts helped lower the bank's cost-to-income ratio to 27%, widening operating margins ahead of debt expansion.
SourcesSimply Wall St: Bank Leumi Le Israel B.M (TASE:LUMI) Could Be 6% Undervalued On €750000000 Covered Bond Pricing (opens in new tab)

Business

Teva's clinical win in celiac disease validates its IL-15 antibody — positioning the drugmaker to capture a first-in-class autoimmune market.

BackgroundCeliac disease is an autoimmune condition triggered by gluten ingestion that currently lacks approved disease-modifying pharmacological treatments. Teva is positioning TEV '408 as a broad immunological asset across multiple gastrointestinal and dermatological indications.

Points
  1. Trial data met primary endpoints by demonstrating mucosal damage reduction in biopsy samples following gluten challenges, proving the antibody reduces gut tissue destruction.
  2. Teva highlighted the molecule as a multi-indication pipeline driver, using the findings to support ongoing clinical trials in vitiligo and other autoimmune conditions.
  3. Phase 2b trial planning is underway to determine optimal dosing parameters, setting up pivotal studies required for international market approvals.
SourcesGlobeNewswire: Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody (opens in new tab)

Unlock the full brief

Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.

Or read free in the appDownload on the App Store